Alexion gets EU approval for two drugs acquired in Synageva deal
September 01, 2015 at 14:52 PM EDT
NEW YORK, Sept 1 (Reuters) - Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for two drugs acquired through the deal, both enzyme-replacement therapies for ultra-rare, life threatening diseases.
